Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension

NCT00311155 is registered in ClinicalTrials.gov with Sankyo Pharma Gmbh as lead sponsor.

NCT NCT00311155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00311155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension
Lead sponsor
Sankyo Pharma Gmbh
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2006
Completion date
April 30, 2008
Enrollment
694 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension